Report Detail
Global CD40 Ligand Market Insights, Forecast to 2025
- RnM2849562 |
- 01 February, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
The global CD40 Ligand market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the CD40 Ligand market based on company, product type, end user and key regions.
This report studies the global market size of CD40 Ligand in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of CD40 Ligand in these regions.
This research report categorizes the global CD40 Ligand market by top players/brands, region, type and end user. This report also studies the global CD40 Ligand market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Biogen, Inc.
Bristol-Myers Squibb Company
eTheRNA Immunotherapies NV
ImmuNext, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Targovax AS
XL-protein GmbH
Market size by Product
ISF-35
LOAd-700
MEDI-4920
MegaCD40L
Others
Market size by End User
Hepatitis B
Bladder Cancer
Liver Cancer
Ovarian Cancer
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global CD40 Ligand market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of CD40 Ligand market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global CD40 Ligand companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of CD40 Ligand submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of CD40 Ligand are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of CD40 Ligand market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 CD40 Ligand Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global CD40 Ligand Market Size Growth Rate by Product
- 1.4.2 ISF-35
- 1.4.3 LOAd-700
- 1.4.4 MEDI-4920
- 1.4.5 MegaCD40L
- 1.4.6 Others
- 1.5 Market by End User
- 1.5.1 Global CD40 Ligand Market Size Growth Rate by End User
- 1.5.2 Hepatitis B
- 1.5.3 Bladder Cancer
- 1.5.4 Liver Cancer
- 1.5.5 Ovarian Cancer
- 1.5.6 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global CD40 Ligand Market Size
- 2.1.1 Global CD40 Ligand Revenue 2014-2025
- 2.1.2 Global CD40 Ligand Sales 2014-2025
- 2.2 CD40 Ligand Growth Rate by Regions
- 2.2.1 Global CD40 Ligand Sales by Regions
- 2.2.2 Global CD40 Ligand Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 CD40 Ligand Sales by Manufacturers
- 3.1.1 CD40 Ligand Sales by Manufacturers
- 3.1.2 CD40 Ligand Sales Market Share by Manufacturers
- 3.1.3 Global CD40 Ligand Market Concentration Ratio (CR5 and HHI)
- 3.2 CD40 Ligand Revenue by Manufacturers
- 3.2.1 CD40 Ligand Revenue by Manufacturers (2014-2019)
- 3.2.2 CD40 Ligand Revenue Share by Manufacturers (2014-2019)
- 3.3 CD40 Ligand Price by Manufacturers
- 3.4 CD40 Ligand Manufacturing Base Distribution, Product Types
- 3.4.1 CD40 Ligand Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers CD40 Ligand Product Type
- 3.4.3 Date of International Manufacturers Enter into CD40 Ligand Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global CD40 Ligand Sales by Product
- 4.2 Global CD40 Ligand Revenue by Product
- 4.3 CD40 Ligand Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global CD40 Ligand Breakdown Data by End User
6 North America
- 6.1 North America CD40 Ligand by Countries
- 6.1.1 North America CD40 Ligand Sales by Countries
- 6.1.2 North America CD40 Ligand Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America CD40 Ligand by Product
- 6.3 North America CD40 Ligand by End User
7 Europe
- 7.1 Europe CD40 Ligand by Countries
- 7.1.1 Europe CD40 Ligand Sales by Countries
- 7.1.2 Europe CD40 Ligand Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe CD40 Ligand by Product
- 7.3 Europe CD40 Ligand by End User
8 Asia Pacific
- 8.1 Asia Pacific CD40 Ligand by Countries
- 8.1.1 Asia Pacific CD40 Ligand Sales by Countries
- 8.1.2 Asia Pacific CD40 Ligand Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific CD40 Ligand by Product
- 8.3 Asia Pacific CD40 Ligand by End User
9 Central & South America
- 9.1 Central & South America CD40 Ligand by Countries
- 9.1.1 Central & South America CD40 Ligand Sales by Countries
- 9.1.2 Central & South America CD40 Ligand Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America CD40 Ligand by Product
- 9.3 Central & South America CD40 Ligand by End User
10 Middle East and Africa
- 10.1 Middle East and Africa CD40 Ligand by Countries
- 10.1.1 Middle East and Africa CD40 Ligand Sales by Countries
- 10.1.2 Middle East and Africa CD40 Ligand Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa CD40 Ligand by Product
- 10.3 Middle East and Africa CD40 Ligand by End User
11 Company Profiles
- 11.1 Biogen, Inc.
- 11.1.1 Biogen, Inc. Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Biogen, Inc. CD40 Ligand Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Biogen, Inc. CD40 Ligand Products Offered
- 11.1.5 Biogen, Inc. Recent Development
- 11.2 Bristol-Myers Squibb Company
- 11.2.1 Bristol-Myers Squibb Company Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Bristol-Myers Squibb Company CD40 Ligand Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Bristol-Myers Squibb Company CD40 Ligand Products Offered
- 11.2.5 Bristol-Myers Squibb Company Recent Development
- 11.3 eTheRNA Immunotherapies NV
- 11.3.1 eTheRNA Immunotherapies NV Company Details
- 11.3.2 Company Business Overview
- 11.3.3 eTheRNA Immunotherapies NV CD40 Ligand Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 eTheRNA Immunotherapies NV CD40 Ligand Products Offered
- 11.3.5 eTheRNA Immunotherapies NV Recent Development
- 11.4 ImmuNext, Inc.
- 11.4.1 ImmuNext, Inc. Company Details
- 11.4.2 Company Business Overview
- 11.4.3 ImmuNext, Inc. CD40 Ligand Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 ImmuNext, Inc. CD40 Ligand Products Offered
- 11.4.5 ImmuNext, Inc. Recent Development
- 11.5 Juno Therapeutics Inc.
- 11.5.1 Juno Therapeutics Inc. Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Juno Therapeutics Inc. CD40 Ligand Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Juno Therapeutics Inc. CD40 Ligand Products Offered
- 11.5.5 Juno Therapeutics Inc. Recent Development
- 11.6 MedImmune, LLC
- 11.6.1 MedImmune, LLC Company Details
- 11.6.2 Company Business Overview
- 11.6.3 MedImmune, LLC CD40 Ligand Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 MedImmune, LLC CD40 Ligand Products Offered
- 11.6.5 MedImmune, LLC Recent Development
- 11.7 Targovax AS
- 11.7.1 Targovax AS Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Targovax AS CD40 Ligand Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Targovax AS CD40 Ligand Products Offered
- 11.7.5 Targovax AS Recent Development
- 11.8 XL-protein GmbH
- 11.8.1 XL-protein GmbH Company Details
- 11.8.2 Company Business Overview
- 11.8.3 XL-protein GmbH CD40 Ligand Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 XL-protein GmbH CD40 Ligand Products Offered
- 11.8.5 XL-protein GmbH Recent Development
12 Future Forecast
- 12.1 CD40 Ligand Market Forecast by Regions
- 12.1.1 Global CD40 Ligand Sales Forecast by Regions 2019-2025
- 12.1.2 Global CD40 Ligand Revenue Forecast by Regions 2019-2025
- 12.2 CD40 Ligand Market Forecast by Product
- 12.2.1 Global CD40 Ligand Sales Forecast by Product 2019-2025
- 12.2.2 Global CD40 Ligand Revenue Forecast by Product 2019-2025
- 12.3 CD40 Ligand Market Forecast by End User
- 12.4 North America CD40 Ligand Forecast
- 12.5 Europe CD40 Ligand Forecast
- 12.6 Asia Pacific CD40 Ligand Forecast
- 12.7 Central & South America CD40 Ligand Forecast
- 12.8 Middle East and Africa CD40 Ligand Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 CD40 Ligand Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on CD40 Ligand . Industry analysis & Market Report on CD40 Ligand is a syndicated market report, published as Global CD40 Ligand Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of CD40 Ligand market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
